文献速递神经核医学肿瘤 PET/CT放射性药物与辐射防护

MRI衰减校正方法在[18F]FDG痴呆评估中的定量与临床影响

Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia.
PubMed 文献 · EJNMMI Res · 2019-08-24

本研究比较三种临床可用和两种研究用MRAC方法与CTAC在[18F]FDG PET/MRI痴呆诊断中的定量差异与视觉诊断一致性;以小脑为参考区时DeepUTE与UCL的z分数平均绝对差最小,视觉诊断中PETCT+MRI与PETDixonBone+MRI一致性达89%;结论推荐临床优先使用DixonBone,但需目视检查其衰减图伪影。

要点

  • 以小脑为参考区时,DeepUTE和UCL的z分数与CTAC平均绝对差最小(0.15σ)。
  • 临床可用MRAC中DixonBone视觉诊断与PETCT一致性67%,加MRI后达89%。
  • DixonBone衰减图可出现伪影,需目视检查以确保定量准确。

核心结论

  • 研究用MRAC方法在[18F]FDG摄取与z分数定量评估上接近CTAC。
  • 临床实施的MRAC方法中,DixonBone应优先用于[18F]FDG PET/MRI痴呆诊断评估。
  • DixonBone衰减图出现伪影时必须目视检查以保证定量正确。

研究设计与样本

  • 比较三种临床可用MRAC(DixonNoBone、DixonBone、UTE)和两种研究MRAC(UCL、DeepUTE)与CTAC的[18F]FDG摄取及z分数定量差异。
  • 由三名核医学医师和一名神经放射科医师进行视觉评估诊断,比较PETCT、PETDeepUTE、PETDixonBone、PETUTE、PETCT+MRI、PETDixonBone+MRI。
  • 比较脑桥和小脑作为归一化参考区。

主要发现

  • 以小脑为参考区时,MRAC与CTAC的z分数平均绝对差分别为0.15±0.11σ(DeepUTE)、0.15±0.12σ(UCL)、0.23±0.20σ(DixonBone)、0.32±0.28σ(DixonNoBone)、0.54±0.40σ(UTE)。
  • 视觉评估中,诊断与PETCT一致的比例为74%(PETDeepUTE)、67%(PETDixonBone)、70%(PETUTE)。
  • PETCT+MRI与PETDixonBone+MRI的诊断一致比例为89%。

关键数值与推荐

  • 以小脑为参考区时,DeepUTE和UCL的z分数平均绝对差最小(0.15σ)。
  • 临床可用MRAC中DixonBone的z分数平均绝对差为0.23±0.20σ。
  • PETDixonBone+MRI与PETCT+MRI的诊断一致比例为89%。

临床怎么用

  • 临床[18F]FDG PET/MRI痴呆评估可优先选用DixonBone进行衰减校正。
  • 使用DixonBone衰减图时应目视检查伪影,以确保定量准确。
  • 研究用MRAC方法(DeepUTE、UCL)定量表现接近CTAC,可供进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Positron emission tomography/magnetic resonance imaging (PET/MRI) is a promising diagnostic imaging tool for the diagnosis of dementia, as PET can add complementary information to the routine imaging examination with MRI. The purpose of this study was to evaluate the influence of MRI-based attenuation correction (MRAC) on diagnostic assessment of dementia with [18F]FDG PET. Quantitative differences in both [18F]FDG uptake and z-scores were calculated for three clinically available (DixonNoBone, DixonBone, UTE) and two research MRAC methods (UCL, DeepUTE) compared to CT-based AC (CTAC). Furthermore, diagnoses based on visual evaluations were made by three nuclear medicine physicians and one neuroradiologist (PETCT, PETDeepUTE, PETDixonBone, PETUTE, PETCT + MRI, PETDixonBone + MRI). In addition, pons and cerebellum were compared as reference regions for normalization. RESULTS: The mean absolute difference in z-scores were smallest between MRAC and CTAC with cerebellum as reference region: 0.15 ± 0.11 σ (DeepUTE), 0.15 ± 0.12 σ (UCL), 0.23 ± 0.20 σ (DixonBone), 0.32 ± 0.28 σ (DixonNoBone), and 0.54 ± 0.40 σ (UTE). In the visual evaluation, the diagnoses agreed with PETCT in 74% (PETDeepUTE), 67% (PETDixonBone), and 70% (PETUTE) of the patients, while PETCT + MRI agreed with PETDixonBone + MRI in 89% of the patients. CONCLUSION: The MRAC research methods performed close to that of CTAC in the quantitative evaluation of [18F]FDG uptake and z-scores. Among the clinically implemented MRAC methods, DixonBone should be preferred for diagnostic assessment of dementia with [18F]FDG PET/MRI. However, as artifacts occur in DixonBone attenuation maps, they must be visually inspected to assure proper quantification.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Øen SK, Keil TM, Berntsen EM, et al. Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia. EJNMMI Res. 2019. PMID: 31446507. doi:10.1186/s13550-019-0553-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。